The present article reviews whether available efficacy and safety data support the
pharmacological treatment of adult attention‐deficit/hyperactivity disorder (ADHD) in patients …

Introduction: Substance use disorder (SUD) is very common amongst patients with attention
deficit hyperactivity disorder (ADHD). The two disorders share partially overlapping features …

This MiniReview reports and discusses the main findings of the author's thesis including a
literature study of long‐term pharmacological treatment of adults with attention deficit …

Background: Drug dependence is frequent in patients with attention deficit hyperactivity
disorder (ADHD). Nevertheless, the efficacy and safety of pharmacological treatments in this …

Objective Substance use disorder (SUD) and attention-deficit/hyperactivity disorder (ADHD)
frequently co-occur, and the presence of ADHD complicates the treatment of the addiction …

How to generalize from randomized placebo controlled trials of ADHD drug treatment in
adults to 'real-world'clinical practice is intriguing. This open-labeled prospective …

Background Attention-deficit/hyperactivity disorder (ADHD) is a behavioral disorder typically
treated with stimulants and atomoxetine. Data on long-term tolerability and safety of such …

The US Food and Drug Administration has approved 3 medications, atomoxetine and the
extended-release formulations of amphetamine salts and dexmethylphenidate, for the …

With increased awareness that attention-deficit/hyperactivity disorder (ADHD) can persist
beyond childhood, pharmacological treatment options for adults have expanded. Short …

There is a substantial body of literature documenting the efficacy of multiple unrelated
pharmacological agents in attention-deficit hyperactivity disorder (ADHD) individuals …